{
    "clinical_study": {
        "@rank": "65340", 
        "arm_group": {
            "arm_group_label": "Ofatumumab combined with SB-485232", 
            "arm_group_type": "Experimental", 
            "description": "Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 100 ug/kg) for 8 weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see\n      what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma."
        }, 
        "brief_title": "Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma", 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have undergone high-dose therapy and autologous PBSCT for treatment of\n             CD20+ lymphoma.\n\n          -  Patients must be between 2-6 months post-transplantation at the time of study\n             registration.\n\n          -  Patients must have at least stable disease (no overt progressive disease) at the time\n             of study registration.\n\n          -  Laboratory values must be within protocol specified ranges.\n\n          -  Females of childbearing potential must have a negative pregnancy test.\n\n          -  Females of childbearing potential and males must use an effective method of\n             contraception from the time of consent until at least 365 days following\n             discontinuation of protocol therapy.\n\n        Exclusion Criteria:\n\n          -  Patient must not have obvious clinical progression of lymphoma after PBSCT as\n             determined by the treating physician.\n\n          -  Cannot be positive for hepatitis B surface antigen, hepatitis B core antibody or HIV\n             antibody.\n\n          -  No major or uncontrolled comorbid conditions as determined by the treating physician:\n             history of ventricular arrhythmias requiring drug or device therapy; uncontrolled\n             angina or symptomatic congestive heart failure; \u2022 severe or uncontrolled infection\n             requiring systemic antibiotic or antifungal therapy or active hepatitis C infection;\n             severe or uncontrolled psychiatric illness.\n\n          -  No known leptomeningeal involvement by lymphoma or current metastatic brain disease.\n\n          -  No Corrected QTc interval > 480 msec.\n\n          -  No known or suspected hypersensitivity to ofatumumab or SB-485232 that in the opinion\n             of the investigator is a contraindication to their participation in the study.\n\n          -  No systemic (oral or parenteral) corticosteroids within 14 days of study entry.\n\n          -  Not receiving concurrent chemotherapy, biologic therapy, radiotherapy, or other\n             investigational therapy.\n\n          -  No previous treatment with SB-485232 or ofatumumab.\n\n          -  No history of other malignancy except for adequately treated non-invasive cancers of\n             the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.\n\n          -  No diabetes mellitus with poor glycemic control (documented hemoglobin A1c >7% within\n             4 weeks prior to study entry)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768338", 
            "org_study_id": "IUCRO-0397", 
            "secondary_id": "1210009882"
        }, 
        "intervention": {
            "arm_group_label": "Ofatumumab combined with SB-485232", 
            "description": "Ofatumumab with escalating doses of SB-485232", 
            "intervention_name": "Ofatumumab combined with SB-485232", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "jweisenb@iupui.edu", 
                "last_name": "Jill Weisenbach, RN", 
                "phone": "317-278-0597"
            }, 
            "contact_backup": {
                "email": "mjrobert@iupui.edu", 
                "last_name": "Michael Robertson, MD", 
                "phone": "317-948-6942"
            }, 
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "Indiana University Melvin and Bren Simon Cancer Center"
            }, 
            "investigator": {
                "last_name": "Michael Robertson, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma", 
        "overall_contact": {
            "email": "jweisenb@iupui.edu", 
            "last_name": "Jill Weisenbach, RN", 
            "phone": "317-278-0597"
        }, 
        "overall_contact_backup": {
            "email": "mjrobert@iupui.edu", 
            "last_name": "Michael Robertson, MD", 
            "phone": "317-948-6942"
        }, 
        "overall_official": {
            "affiliation": "Indiana University Melvin and Bren Simon Cancer Center", 
            "last_name": "Michael Robertson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 which uses a scale of 1 (mild) to 5 (caused death).", 
            "measure": "To evaluate the the number of subjects with adverse events who receive SB-485232 when given in combination with ofatumumab", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768338"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Biologic effects will be assessed by flow cytometric analysis of PBMCs and ELISA tests to measure plasma cytokines and chemokines.", 
            "measure": "To evaluate the biologic effects of SB-485232 given in combination with ofatumumab", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Indiana University", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Indiana University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}